Patents Assigned to Merck Patent GmbH
  • Publication number: 20070160521
    Abstract: The invention relates to the use of core/shell particles, the core of which essentially comprises a degradable polymer with an essentially mono-disperse size distribution and the shell of which forms a matrix, which can be pyrolysed to give a carbon matrix, for the production of shaped bodies with regularly-arranged cavities and the corresponding shaped bodies.
    Type: Application
    Filed: November 10, 2004
    Publication date: July 12, 2007
    Applicant: MERCK PATENT GMBH
    Inventors: Holger Winkler, Goetz Hellmann, Tilmann Ruhl, Peter Spahn
  • Publication number: 20070161623
    Abstract: Novel compounds of the formula (I), in which X—Y-D-E, R1, R2 and R3 have the meanings indicated in Patent claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumours
    Type: Application
    Filed: January 7, 2005
    Publication date: July 12, 2007
    Applicant: MERCK PATENT GMBH
    Inventors: Werner Mederski, Christos Tsaklakidis, Dieter Dorsch, Bertram Cezanne, Johannes Gleitz
  • Publication number: 20070161677
    Abstract: The present invention relates to bisarylurea derivatives of formula (I), the use of the compounds of formula (I) as inhibitors of raf-kinase, the use of the compounds of formula (I) for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient.
    Type: Application
    Filed: January 17, 2005
    Publication date: July 12, 2007
    Applicant: Merck Patent GmbH
    Inventor: Hans-Peter Buchstaller
  • Patent number: 7241505
    Abstract: Hybrid sol comprising [SiOx(OH)y]n particles, where 0<y<4 and 0<x<2, which consist of a mixture of a first fraction of particles having a particle size of 4–15 nm and a second fraction of particles having a mean particle size of 15–60 nm, water and a solvent; obtainable by hydrolytic polycondensation of tetraalkoxysilanes in an aqueous, solvent-containing medium with addition of a monodisperse silicon oxide hydroxide sol having a mean particle size of 15–60 nm and a maximum standard deviation of 20%, and the preparation and use thereof.
    Type: Grant
    Filed: September 19, 2002
    Date of Patent: July 10, 2007
    Assignee: Merck Patent, GmbH
    Inventors: Walther Glaubitt, Monika Kursawe, Andreas Gombert, Thomas Hofmann
  • Patent number: 7241450
    Abstract: The invention relates to the identification and characterization of a grass-pollen allergen, and to the recombinant DNA molecule encoding therefore, and to corresponding DNA and peptide sequences.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: July 10, 2007
    Assignee: Merck Patent GmbH
    Inventors: Helmut Fiebig, Roland Suck, Oliver Cromwell
  • Patent number: 7241503
    Abstract: An iridescent multilayer pigment having at least two or more layers of metal oxides containing one or more metals selected from Ce, Sn, Ti, Fe, Zn and Zr which are coated onto the surface of thin platelet-like substrates. The inventive pigments show high brilliance and high chroma, in particular in cases in which thin platelet-like substrates having a fine average particle diameter are used. The pigment is useful in paints, printing inks, lacquers, plastics, dopants for laser marking, non-dusting pigment products, non-dusting pigment granules or cosmetics.
    Type: Grant
    Filed: November 21, 2003
    Date of Patent: July 10, 2007
    Assignee: Merck Patent GmbH
    Inventor: Tamio Noguchi
  • Publication number: 20070154473
    Abstract: Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.
    Type: Application
    Filed: December 29, 2006
    Publication date: July 5, 2007
    Applicant: Merck Patent GmbH
    Inventors: Michael Super, Jonathan Davis, Pascal Stein
  • Publication number: 20070154453
    Abstract: Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
    Type: Application
    Filed: December 29, 2006
    Publication date: July 5, 2007
    Applicant: Merck Patent GmbH
    Inventors: Gordon Webster, Suzanne McKenzie, Kin-Ming Lo, Pascal Stein
  • Patent number: 7238310
    Abstract: The invention relates to the use of gelation moulds made from hydrophobicized glass tubes for the production of monolithic mouldings as sorbents for chromatography.
    Type: Grant
    Filed: May 23, 2001
    Date of Patent: July 3, 2007
    Assignee: Merck Patent GmbH
    Inventors: Dieter Lubda, Karin Cabrera
  • Patent number: 7235199
    Abstract: The invention relates to a process for the production of chromatography columns or capillaries containing sorbents of monolithic mouldings which can remain directly in their gelation mould after production. This is achieved by the process according to the invention, in which the gelation mould is repeatedly filled with the monomer sol.
    Type: Grant
    Filed: May 16, 2001
    Date of Patent: June 26, 2007
    Assignee: Merck Patent GmbH
    Inventors: Dieter Lubda, Egbert Mueller
  • Publication number: 20070135635
    Abstract: The invention relates to a method for the production of high-purity, heteroleptic, ortho-metallated, organometallic compounds of application as a functional material for colouring components in a wide range of applications within the widest sense of the electronics industry. A method is thus used for the cleavage of a bridged metal dimer with organometallic substances. Dihalo complexes, which may be used as monomers for polymerisations, in particular, may be produced thus.
    Type: Application
    Filed: October 21, 2004
    Publication date: June 14, 2007
    Applicant: Merck Patent GmbH
    Inventors: Philipp Stössel, Arne Busing, Ingrid Bach
  • Patent number: 7226592
    Abstract: The invention relates to novel bispecific antibodies and their use in tumor therapy. The novel antibodies have the ability to bind to ErbB receptors, preferably ErbB1 receptors, which are overexpressed on many cancer tissues. Since the different specificities of the antigen-binding sites are directed to different epitopes within the binding domain of same or different ErbB receptors, these antibodies are more effective with respect to inhibition and down-regulation of the ErbB receptor and the corresponding signaling cascade.
    Type: Grant
    Filed: October 9, 2003
    Date of Patent: June 5, 2007
    Assignee: Merck Patent GmbH
    Inventor: Hans-Georg Kreysch
  • Patent number: 7226503
    Abstract: The present invention relates to effect pigments based on thin glass flakes and to a method for the production of such pigments. The resulting pigment can be used in any application for which pearlescent pigments have been heretofore used such as, for example, in plastics, paints, inks, cosmetic formulations, coatings including solvent or waterborne automotive paint systems, powder coatings, inks and agriculture foils.
    Type: Grant
    Filed: April 11, 2002
    Date of Patent: June 5, 2007
    Assignee: Merck Patent GmbH
    Inventors: Ralf Anselmann, Klaus Ambrosius, Marcus Mathias
  • Publication number: 20070123690
    Abstract: The present invention relates to conjugated polymers which comprise coumarin structural units or related units of the formula (1). The materials according to the invention exhibit significantly higher photostability than materials in accordance with the prior art and are therefore more suitable for use in polymeric organic light-emitting diodes.
    Type: Application
    Filed: November 24, 2004
    Publication date: May 31, 2007
    Applicant: Merck Patent GmbH
    Inventors: Amir Parham, Susanne Heun, Aurelie Falcou, Heinrich Becker
  • Publication number: 20070122653
    Abstract: The present invention describes electroluminescent elements comprising cathode and anode and at least one emission layer, where this comprises at least one matrix material A comprising certain elements and at least one emitter layer B which emits light from the triplet state.
    Type: Application
    Filed: February 10, 2005
    Publication date: May 31, 2007
    Applicant: Merck Patent GmbH
    Inventors: Esther Breuning, Anja Gerhard, Horst Vestweber, Philipp Stoessel
  • Patent number: 7223484
    Abstract: The present invention describes novel 2,1,3-benzothiadiazole-containing compounds. Such compounds can be used as active components (=functional materials) in a variety of different applications which can in the widest sense be considered part of the electronics industry.
    Type: Grant
    Filed: June 14, 2003
    Date of Patent: May 29, 2007
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stössel, Amir Parham, Horst Vestweber, Hubert Spreitzer
  • Publication number: 20070114915
    Abstract: The invention relates to the improvement of phosphorescing organic electroluminescent devices characterized in that the emission layer, which consists of a matrix material which is doped with at least one phosphorescing emitter, directly adjoins an electrically conducting layer.
    Type: Application
    Filed: November 24, 2004
    Publication date: May 24, 2007
    Applicant: Merck Patent GmbH
    Inventors: Anja Gerhard, Horst Vestweber, Philipp Stossel
  • Publication number: 20070104689
    Abstract: The present invention provides compositions and methods that elicit an immune response against diseased cells. In particular, the present invention provides compositions and methods for the presentation of a peptide related to survivin on antigen-presenting cells. Presentation of the peptide leads to an immune response in a mammal against cells such as tumor cells overexpressing survivin.
    Type: Application
    Filed: September 26, 2006
    Publication date: May 10, 2007
    Applicant: Merck Patent GmbH
    Inventors: Stephen Gillies, Thore Hettmann, Pascal Stein, Stephan Klinz
  • Publication number: 20070099910
    Abstract: The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X? have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.
    Type: Application
    Filed: October 14, 2004
    Publication date: May 3, 2007
    Applicant: Merck Patent GmbH
    Inventors: Guenter Hoelzemann, Helene Crassier, Karl-August Ackermann, Wolfgang Staehle, Alfred Jonczyk, Wilfried Rautenberg, Francesc Mitjans, Elisabet Rosell-Vives, Jaume Adan, Marta Soler Riera
  • Patent number: 7211302
    Abstract: The invention relates to a photostable liquid-crystalline medium comprising at least one compound of the formula I and at least one compound of the formula II and to the use thereof for electro-optical purposes, and to displays containing this medium.
    Type: Grant
    Filed: September 25, 2003
    Date of Patent: May 1, 2007
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Ulrich Heywang, Detlef Pauluth, Michael Heckmeier, Peer Kirsch, Elvira Montenegro